Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc. BofA…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
